B
REGN icon

Bailard’s Regeneron Pharmaceuticals REGN Stock Holding History

Bailard’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.61M Buy
3,378
+4
+0.1% +$3.06K 0.06% 208
2025
Q4 		$2.6M Sell
3,374
-105
-3% -$71.3K 0.06% 204
2025
Q3 		$1.96M Sell
3,479
-122
-3% -$69K 0.04% 242
2025
Q2 		$1.89M Sell
3,601
-433
-11% -$242K 0.04% 248
2025
Q1 		$2.56M Sell
4,034
-9,388
-70% -$6.46M 0.07% 206
2024
Q4 		$9.56M Buy
13,422
+1,236
+10% +$1.04M 0.24% 95
2024
Q3 		$12.8M Buy
12,186
+98
+0.8% +$109K 0.33% 72
2024
Q2 		$12.7M Sell
12,088
-56
-0.5% -$54.3K 0.35% 64
2024
Q1 		$11.7M Buy
12,144
+41
+0.3% +$39K 0.32% 75
2023
Q4 		$10.6M Sell
12,103
-31
-0.3% -$25.5K 0.31% 74
2023
Q3 		$9.99M Buy
12,134
+294
+2% +$231K 0.33% 65
2023
Q2 		$8.51M Buy
11,840
+2,486
+27% +$1.92M 0.3% 76
2023
Q1 		$7.69M Buy
9,354
+284
+3% +$214K 0.28% 84
2022
Q4 		$6.54M Buy
9,070
+207
+2% +$153K 0.25% 92
2022
Q3 		$6.11M Buy
8,863
+2,732
+45% +$1.72M 0.25% 91
2022
Q2 		$3.62M Buy
6,131
+5,831
+1,944% +$3.79M 0.14% 136
2022
Q1 		$210K Buy
+300
New +$190K 0.01% 662
2016
Q1 		– Sell
-1,000
Closed -$543K – 332
2015
Q4 		$543K Buy
+1,000
New +$542K 0.24% 134

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bailard's REGN Position: Q1 2026 in Review

Bailard increased its Regeneron Pharmaceuticals (REGN) stake by 0.12% in Q1 2026, buying an estimated $3.06K and bringing the position to 3,378 shares worth $2.61M. The position accounts for 0.06% of the portfolio, ranked #208.

Bailard first reported a position in REGN in Q4 2015 and has held it in 18 quarters since. The position peaked at $12.8M in Q3 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Bailard held 3,378 shares of Regeneron Pharmaceuticals worth $2.61M as of Q1 2026.
  • Bailard bought 4 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $3.06K.
  • Regeneron Pharmaceuticals made up 0.06% of Bailard's portfolio in Q1 2026, its #208 holding.
  • Bailard first reported a position in Regeneron Pharmaceuticals in Q4 2015 and has held it in 18 quarters since.
  • Bailard's Regeneron Pharmaceuticals position peaked at $12.8M in Q3 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Bailard's 13F filing for Q1 2026, filed 11 May 2026.